JP2021534099A5 - - Google Patents

Info

Publication number
JP2021534099A5
JP2021534099A5 JP2021506624A JP2021506624A JP2021534099A5 JP 2021534099 A5 JP2021534099 A5 JP 2021534099A5 JP 2021506624 A JP2021506624 A JP 2021506624A JP 2021506624 A JP2021506624 A JP 2021506624A JP 2021534099 A5 JP2021534099 A5 JP 2021534099A5
Authority
JP
Japan
Prior art keywords
alkyl
alkoxy
perfluoro
hydrogen
amino
Prior art date
Application number
JP2021506624A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020033359A5 (https=
JP2021534099A (ja
JP7422737B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/045229 external-priority patent/WO2020033359A1/en
Publication of JP2021534099A publication Critical patent/JP2021534099A/ja
Publication of JPWO2020033359A5 publication Critical patent/JPWO2020033359A5/ja
Publication of JP2021534099A5 publication Critical patent/JP2021534099A5/ja
Priority to JP2024004449A priority Critical patent/JP2024056694A/ja
Application granted granted Critical
Publication of JP7422737B2 publication Critical patent/JP7422737B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021506624A 2018-08-06 2019-08-06 神経変性疾患を治療するためのＰｐａｒｇｃ１ａ活性化剤としての２‐アリールベンゾイミダゾール Active JP7422737B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024004449A JP2024056694A (ja) 2018-08-06 2024-01-16 神経変性疾患を治療するためのＰｐａｒｇｃ１ａ活性化剤としての２‐アリールベンゾイミダゾール

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862714962P 2018-08-06 2018-08-06
US62/714,962 2018-08-06
PCT/US2019/045229 WO2020033359A1 (en) 2018-08-06 2019-08-06 2-arylbenzimidazoles as ppargc1a activators for treating neurodegenerative diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024004449A Division JP2024056694A (ja) 2018-08-06 2024-01-16 神経変性疾患を治療するためのＰｐａｒｇｃ１ａ活性化剤としての２‐アリールベンゾイミダゾール

Publications (4)

Publication Number Publication Date
JP2021534099A JP2021534099A (ja) 2021-12-09
JPWO2020033359A5 JPWO2020033359A5 (https=) 2022-08-12
JP2021534099A5 true JP2021534099A5 (https=) 2022-08-12
JP7422737B2 JP7422737B2 (ja) 2024-01-26

Family

ID=69413327

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021506624A Active JP7422737B2 (ja) 2018-08-06 2019-08-06 神経変性疾患を治療するためのＰｐａｒｇｃ１ａ活性化剤としての２‐アリールベンゾイミダゾール
JP2024004449A Pending JP2024056694A (ja) 2018-08-06 2024-01-16 神経変性疾患を治療するためのＰｐａｒｇｃ１ａ活性化剤としての２‐アリールベンゾイミダゾール

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024004449A Pending JP2024056694A (ja) 2018-08-06 2024-01-16 神経変性疾患を治療するためのＰｐａｒｇｃ１ａ活性化剤としての２‐アリールベンゾイミダゾール

Country Status (13)

Country Link
US (3) US12195432B2 (https=)
EP (1) EP3833344A4 (https=)
JP (2) JP7422737B2 (https=)
KR (1) KR20210068399A (https=)
CN (2) CN112805000A (https=)
AU (1) AU2019319745B2 (https=)
BR (1) BR112021002165A2 (https=)
CA (1) CA3108773A1 (https=)
IL (3) IL280664B2 (https=)
MX (2) MX2021001456A (https=)
SG (1) SG11202101285YA (https=)
TW (1) TWI904076B (https=)
WO (1) WO2020033359A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12195432B2 (en) 2018-08-06 2025-01-14 The Board Of Trustees Of The Leland Stanford Junior University 2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases
KR20220154772A (ko) * 2020-03-13 2022-11-22 주식회사 바이오오케스트라 Pgc-1a 발현을 사용하는 진단 방법
CN112933232A (zh) * 2021-02-02 2021-06-11 袁玉佳 PGC-1α激活TFEB介导的自噬在制备治疗急性肾损伤的药物中的应用
EP4426295A1 (en) * 2021-11-02 2024-09-11 Tranquis Therapeutics, Inc. Selection and treatment of subjects having a circulating myeloid cell inflammatory phenotype
US20250262189A1 (en) * 2022-04-22 2025-08-21 Rdiscovery, LLC Treatment of diseases associated with reductive stress
EP4618982A1 (en) * 2022-11-18 2025-09-24 GOJO, Satoshi Uses of zln-005 and related compounds
WO2024118936A1 (en) * 2022-12-02 2024-06-06 Tranquis Therapeutics, Inc. 2-arylbenzimidazole compounds for the treatment of hemoglobinopathies

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE614236A (https=) 1961-03-01
FR1569337A (https=) * 1968-06-18 1969-05-30
US4038396A (en) * 1975-02-24 1977-07-26 Merck & Co., Inc. Anti-inflammatory oxazole[4,5-b]pyridines
GB1584296A (en) 1976-12-07 1981-02-11 Kanebo Ltd 2-substituted benzimidazole compounds
NZ234564A (en) 1986-11-21 1991-04-26 Haessle Ab 1-substituted benzimidazoles and pharmaceutical compositions
DE3830060A1 (de) 1988-09-03 1990-03-15 Boehringer Mannheim Gmbh 2-phenylbenzimidazole - verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel
US5552426A (en) 1994-04-29 1996-09-03 Eli Lilly And Company Methods for treating a physiological disorder associated with β-amyloid peptide
JPH09169729A (ja) * 1995-12-19 1997-06-30 Green Cross Corp:The 非ペプチド型インターロイキン８拮抗剤
CA2258728C (en) * 1996-06-19 2011-09-27 Rhone Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
JP2000143635A (ja) * 1998-06-10 2000-05-26 Takeda Chem Ind Ltd 血管新生阻害剤
JP2000095767A (ja) * 1998-09-28 2000-04-04 Takeda Chem Ind Ltd 性腺刺激ホルモン放出ホルモン拮抗剤
DE59911249D1 (de) 1998-11-03 2005-01-13 Abbott Gmbh & Co Kg Substituierte 2-phenylbenzimidazole, deren herstellung und anwendung
US20070004713A1 (en) * 2000-12-07 2007-01-04 Bernard Barlaam Therapeutic benimidazole compounds
DE10134775A1 (de) * 2001-07-06 2003-01-30 Schering Ag 1-Alkyl-2.aryl-benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate
SE0301371D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab New Compounds
KR20070032700A (ko) 2004-05-20 2007-03-22 폴드알엑스 파마슈티칼스, 인크. 트랜스티레틴을 안정화하고 트랜스티레틴 미스폴딩을억제하기 위한, ２-((헤테로)아릴)-벤즈옥사졸 화합물 및유도체, 그리고 조성물 및 방법
RU2007101509A (ru) 2004-06-17 2008-07-27 Уайт (Us) Способ получения антагонистов рецепторов гормона, высвобождающего гонадотропин
WO2006122546A1 (de) * 2005-05-18 2006-11-23 Forschungsverbund Berlin E.V. Nicht-peptidische inhibitoren der akap-pka-wechselwirkung
CA2616512A1 (en) 2005-07-28 2007-02-08 Intervet International B.V. Novel benzimidazole (thio) carbamates with antiparasitic activity and the synthesis thereof
EP1910385B1 (en) 2005-08-04 2013-07-24 Sirtris Pharmaceuticals, Inc. Benzothiazoles and thiazolopyridines as sirtuin modulators
US7915299B2 (en) 2006-11-15 2011-03-29 High Point Pharmaceuticals, Llc 2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes
GB0807103D0 (en) 2008-04-18 2008-05-21 Univ Bradford The Compounds
JP2012529449A (ja) * 2009-06-11 2012-11-22 シエナ ビオテク ソシエタ ペル アチオニ ヘッジホッグ経路アンタゴニストおよびそれらの治療的応用
WO2011047129A1 (en) * 2009-10-15 2011-04-21 Southern Research Institute Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such
BR112012010738A2 (pt) * 2009-11-06 2019-09-24 Univ Vanderbilt ''aril e heteroaril sulfonas como potenciadores alostéricos de mglur4,composições e métodos de tratamento de disfunção neurológica''
GB201009656D0 (en) 2010-06-09 2010-07-21 Univ St Andrews Carboxylation catalysts
JP5083393B2 (ja) 2010-09-16 2012-11-28 カシオ計算機株式会社 画像表示装置及びプログラム
EP2651405A2 (en) * 2010-12-14 2013-10-23 Electrophoretics Limited Casein kinase 1 (ck1 ) inhibitors
US8865754B2 (en) * 2011-03-03 2014-10-21 Proteotech Inc. Compounds for the treatment of neurodegenerative diseases
AU2013250726B2 (en) 2012-04-20 2017-01-05 Advinus Therapeutics Limited Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
EA201590482A1 (ru) * 2012-09-05 2015-07-30 Байер Кропсайенс Аг Применение замещенных 2-амидобензимидазолов, 2-амидобензоксазолов и 2-амидобензотиазолов или их солей в качестве биологически активных веществ против абиотического стресса растений
KR101435496B1 (ko) 2012-10-22 2014-08-28 한국과학기술연구원 미토콘드리아 기능 조절제로서의 벤즈이미다졸 유도체
GB201302927D0 (en) * 2013-02-20 2013-04-03 Cancer Therapeutics Crc Pty Ltd Compounds
CN103113307B (zh) * 2013-02-27 2015-08-05 南京大学 苯并咪唑类化合物及其应用
US10022357B2 (en) 2013-04-29 2018-07-17 The General Hospital Corporation Amyloid precursor protein MRNA blockers for treating Down syndrome and Alzheimer's disease
US10272070B2 (en) 2014-10-14 2019-04-30 The Board of Trustees of the Leland Stanford Junio r University Method for treating neurodegenerative diseases
CN104873500A (zh) 2015-04-29 2015-09-02 中国人民解放军第四军医大学 化合物zln005的用途
CA2984971A1 (en) * 2015-05-11 2016-11-17 Kancera Ab Benzimidazole derivates useful as inhibitors of mammalian histone deacetylase activity
PT3390367T (pt) * 2015-12-15 2020-09-23 Univ Leland Stanford Junior Método para prevenir e/ou tratar enfraquecimento cognitivo e neuroinflamação associados ao envelhecimento
RU2747431C2 (ru) * 2015-12-22 2021-05-05 Кансера Аб Бициклические гидроксамовые кислоты, полезные в качестве ингибиторов активности деацетилазы гистонов млекопитающих
JP2018083799A (ja) 2016-11-15 2018-05-31 バイオエレクトロン テクノロジー コーポレイション ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩
US12195432B2 (en) 2018-08-06 2025-01-14 The Board Of Trustees Of The Leland Stanford Junior University 2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases

Similar Documents

Publication Publication Date Title
JP2021534099A5 (https=)
ES2878118T3 (es) Inhibidores de beta-lactamasa
JP5255983B2 (ja) カルバペネム系抗生物質、組成物及び調製方法
JP2020507589A5 (https=)
MXPA01006474A (es) Derivados colquinol como agentes perjudiciales vasculares.
WO2009039981A3 (en) Use of (arg 8) vasopressin to treat eg s. pneumoniae infection
RU94041223A (ru) Средство для лечения мотонейроновых заболеваний
WO2009033784A3 (en) Use of apelin-13 (qrprlshkgpmpf) and optionally aplha-casein (90-96) as a therapeutic agents in eg the treatment of hiv infection
AU2002359164A8 (en) Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
WO2009033665A3 (en) Use of a rgd-peptide and/or parathyroid hormone (1-34 ) as anti-hiv agent
IL187183A0 (en) Pharmaceutical formulation of apomorphine for buccal administration
CN107105660A (zh) 使用替唑尼特、其类似物或盐的前药的治疗组合物和治疗方法
WO2009033785A3 (en) Use of alpha-casein (90-96) as a therapeutic agent in eg the treatment of hiv infection
JP2015521617A5 (https=)
RU2007101653A (ru) Производные 1-азабицикло[3.3.1]нонанов
MX2025010188A (es) Moduladores farmaceuticamente activos de la nedilacion de culina mediada por dcn1/2 de tipo pirazolo-piridona
UA98462C2 (ru) Способы лечения аутоиммунных заболеваний с использованием слитой молекулы taci-ig
KR970705563A (ko) 항바이러스제로서의 4-(2-아미노-6-(시클로프로필아미노)-9H-푸린-9-일)-2-시클로펜텐-1-메탄올 숙시네이트(4-(2-Amino-6-(Cyclopropylamino)-9H-Purin-9-yl)-2-Cyclopentene-1-Methanol Succinate as Antiviral Agent)
CA2979891A1 (en) Boron-containing small molecules as antiprotozoal agents
JP5297815B2 (ja) 医薬組成物
DE2964903D1 (en) 2-lower alkyl-7-substituted-2 or 3-cephem-4-carboxylic acid compounds, processes for their preparation and pharmaceutical compositions containing them
JPWO2020033359A5 (https=)
JP2004026678A (ja) ２型糖尿病治療剤
JP2003522786A5 (https=)
EP2909216B1 (en) Compositions and methods for improving glucose uptake